We are live on !
Find out more
Sofinnova Investments Portfolio holdings
AUM
$1.93B
Turnover
49.43%
1-Year Est. Return
134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
(-26%)
Cap. Flow
-$415M
Cap. Flow % of AUM
Cap. Flow %
-21.46%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30
Avg Time Held
Equity + Options
1.5
years
Top 10 Avg Time Held
Equity + Options
1.3
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1.4
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$87.5M |
| 2 |
Seaport Therapeutics
SPTX
|
+$62.7M |
| 3 |
Gilead Sciences
GILD
|
+$45.2M |
| 4 |
AnaptysBio
ANAB
|
+$14.9M |
| 5 |
Abbott
ABT
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$89.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$63.8M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$51M |
| 4 |
United Therapeutics
UTHR
|
+$47.1M |
| 5 |
Biogen
BIIB
|
+$42.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.78% |
| 2 | Miscellaneous | 3.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Vaxcyte
PCVX
$9.5B
| – | – |
-50,600
| Closed | -$2.94M | – |
|
77
CALL
Pfizer
PFE
$169B
| – | – |
-800,000
| Closed | -$22.5M | – |
|
78
PUT
Invesco QQQ Trust
QQQ
$487B
| – | – |
-150,000
| Closed | -$86.6M | – |
|
79
CALL
Replimune Group
REPL
$1.21B
| – | – |
-1,015,400
| Closed | -$7.77M | – |
|
80
Roivant Sciences
ROIV
$26.3B
| – | – |
-477,995
| Closed | -$13.2M | – |
|
81
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-14,689
| Closed | -$492K | – |
|
82
Stryker
SYK
$115B
| – | – |
-44,480
| Closed | -$14.6M | – |
|
83
Tango Therapeutics
TNGX
$3.79B
| – | – |
-395,081
| Closed | -$8.27M | – |
|
|
84
PUT
United Therapeutics
UTHR
$25.1B
| – | – |
-80,300
| Closed | -$47.6M | – |
|
85
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.7B
| – | – |
-1,050,000
| Closed | -$134M | – |
|
86
Xenon Pharmaceuticals
XENE
$3.49B
| – | – |
-305,216
| Closed | -$17.7M | – |
|
87
Zymeworks
ZYME
$2.05B
| – | – |
-1,610
| Closed | -$40.3K | – |
|
Similar funds
TCM
Sofinnova Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.
Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.
- Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
- Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
- Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
- Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
- Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
- Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
- Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.
Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.